Company Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart.
It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya.
The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases.
It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia.
It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology.
The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and collaboration Revna Biosciences for lung cancer treatment.
AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
| Country | United Kingdom |
| Founded | 1992 |
| IPO Date | May 12, 1993 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 94,300 |
| CEO | Pascal Claude Soriot |
Contact Details
Address: 1 Francis Crick Avenue, Cambridge Biomedical Campus Cambridge, CB2 0AA United Kingdom | |
| Phone | 44 20 3749 5000 |
| Website | astrazeneca.com |
Stock Details
| Ticker Symbol | AZN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000901832 |
| CUSIP Number | 046353108 |
| ISIN Number | US0463531089 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Pascal Claude Roland Soriot D.V.M., M.B.A. | Chief Executive Officer and Executive Director |
| Dr. Aradhana Sarin M.D. | Chief Financial Officer and Executive Director |
| Pam P. Cheng | Executive Vice President of Global opt. and IT, Chief Sust. Officer and Member of External Sust.Adv. Board |
| Andrew P. Barnett | Head of Investor Relations |
| Jeffrey Pott J.D. | CHRO, Chief Compliance Officer, General Counsel and Member of External Sustainability Advisory Board |
| Dr. Ruud Dobber Ph.D. | Executive Vice-President of BioPharmaceuticals Business Unit |
| Dr. Susan Mary Galbraith M.D., Ph.D. | Executive Vice President of Oncology Research & Development |
| Iskra Reic | Executive Vice President of International |
| David Fredrickson | Executive Vice-President of Oncology Haematology Business Unit |
| Ruth March | Senior Vice President of Precision Medicine - Research & Development Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 1, 2025 | 6-K | Report of foreign issuer |
| Jul 29, 2025 | 6-K | Report of foreign issuer |
| Jul 24, 2025 | 6-K | Report of foreign issuer |
| Jul 22, 2025 | 6-K | Report of foreign issuer |
| Jul 16, 2025 | 6-K | Report of foreign issuer |
| Jul 14, 2025 | 6-K | Report of foreign issuer |
| Jul 7, 2025 | 6-K | Report of foreign issuer |
| Jul 1, 2025 | 6-K | Report of foreign issuer |
| Jun 26, 2025 | 11-K | Annual report of employee stock purchase, savings and similar plans |
| Jun 24, 2025 | 6-K | Report of foreign issuer |